Pragmatic Trials: Practical Answers to "Real-world" Questions With Harold C. Sox, MD

Pragmatic Trials: Practical Answers to "Real-...

Up next

Interpretation of Clinical Trials That Stopped Early With Dr Viele

Kert Viele, PhD, director and senior statistical scientist at Berry Consultants, discusses "Interpretation of Clinical Trials That Stopped Early" with JAMA Statistical Editor Roger J. Lewis, MD, PhD. Related Content: Interpretation of Clinical Trials That Stopped Early 

Test-Negative Study Designs for Evaluating Vaccine Effectiveness With Dr Dean

Natalie Exner Dean, PhD, Associate Professor, Rollins School of Public Health, Emory University, discusses Test-Negative Study Designs for Evaluating Vaccine Effectiveness with JAMA Statistical Editor Roger J. Lewis, MD, PhD. Related Content: Test-Negative Study Designs for Evalu ...  Show more

Recommended Episodes

The Combination of Atomoxetine and Oxybutynin Greatly Reduces OSA Severity
Out of the Blue: An AJRCCM Podcast

Dr. John Fleetham is joined by Luigi Taranto Montemurro, MD, Andrew Wellman, MD, PhD, and Seva Polotsky, MD, PhD to discuss the impact the combination of Atomoxetine and Oxybutynin has on reducing the severity of obstructive sleep apnea. 

Optimizing NTM Care: Expert Insights on Diagnosis and Treatment
Deep Breaths: Updates from CHEST

Guest: Ashwin Basavaraj, MD Guest: Keren Bakal, MD Guest: Nathan Falk, MD, MBA, FAAFP Guest: Amy Springer, NP Often mistaken for COPD or asthma, bronchiectasis and nontuberculous mycobacteria (NTM) can be difficult to recognize and test for, often delaying diagnosis and effective ...  Show more

The Real Truth About Menopause Treatments | Dr. Mary Claire Haver
The Dr. Gabrielle Lyon Show

Dr. Mary Claire Haver is board certified in Obstetrics and Gynecology and is a Certified Culinary Medicine Specialist from Tulane University. She is a Louisiana State University Medical Center graduate and completed her Obstetrics and Gynecology residency at the University of Tex ...  Show more

Ep. 267 Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill
BackTable Urology

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ...  Show more